Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jan De Witte Insider Profile
4 Followers
Jan De Witte, Director at Resmed, holds 7.52K shares in Resmed (Ticker: RMD), holds 18.35K shares in Integra Lifesciences (Ticker: IART). Most recently, Jan De Witte Sold ― shares of Resmed on May 17, 2024 for an estimated value of 78.58K.
Profitable Transactions
1 out of 2 Profitable Transactions
Average Return
-6.80%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Jan De Witte holds in companies
Most Profitable Insider Trade
The most profitable trade made by Jan De Witte
Jan De Witte's Trading History
Resmed
May 17, 2024
Director
Informative Sell
78.58K
$1.53M
Integra Lifesciences
Mar 13, 2024
President & CEO, Director
Uninformative Buy
―
$575.09K
List of latest transactions for each holding click on a transaction to see Jan De Witte's performance on stock
You May Also Like
Jan De Witte insider profile FAQ
What is the percentage of profitable transactions made by Jan De Witte?
The percentage of profitable transactions made by Jan De Witte is 50%.
What is the average return per transaction made by Jan De Witte?
The average return per transaction made by Jan De Witte is -6.80%.
What stocks does Jan De Witte hold?
Jan De Witte holds: RMD, IART stocks.
What was Jan De Witte’s latest transaction?
Jan De Witte latest transaction was an Informative Sell of $78.58K.
What was Jan De Witte's most profitable transaction?
Jan De Witte’s most profitable transaction was an Informative Sell of RMD stock on May 17, 2024. The return on the trade was 7.00%.
What is Jan De Witte's role in Resmed?
Jan De Witte's role in Resmed is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.